Immune Pharmaceuticals (IMNP) and XenoPort (XNPT) Critical Comparison
Immune Pharmaceuticals (NASDAQ: IMNP) and XenoPort (NASDAQ:XNPT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.
This is a summary of recent recommendations for Immune Pharmaceuticals and XenoPort, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Immune Pharmaceuticals presently has a consensus target price of $3.00, suggesting a potential upside of 268.37%. Given Immune Pharmaceuticals’ higher probable upside, equities analysts clearly believe Immune Pharmaceuticals is more favorable than XenoPort.
This table compares Immune Pharmaceuticals and XenoPort’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Immune Pharmaceuticals and XenoPort’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Immune Pharmaceuticals||N/A||N/A||-$12.48 million||($6.87)||-0.12|
Institutional & Insider Ownership
3.4% of Immune Pharmaceuticals shares are owned by institutional investors. 6.7% of Immune Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
Immune Pharmaceuticals has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, XenoPort has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500.
Immune Pharmaceuticals beats XenoPort on 6 of the 8 factors compared between the two stocks.
Immune Pharmaceuticals Company Profile
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
XenoPort Company Profile
XenoPort, Inc. is a biopharmaceutical company. The Company is focused on commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets in the United States. The Company’s segment is the development and commercialization of product candidates for the treatment of neurological and other disorders. Its development-stage product candidates include XP23829, XP21279 and arbaclofen placarbil. HORIZANT has been approved by the United States Food and Drug Administration for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. XP23829 is a fumaric acid ester compound and a prodrug of metabolite monomethyl fumarate being developed for the treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or patients with relapsing forms of multiple sclerosis. XP21279 is a Transported Prodrug of levodopa being developed for the treatment for patients with idiopathic Parkinson’s disease.
Receive News & Stock Ratings for Immune Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.